Singapore Markets open in 3 hrs 38 mins

Straits Times Index
3,239.03
+26.39(+0.82%)
S&P 500
3,977.53
+6.54(+0.16%)
Dow
32,432.08
+194.55(+0.60%)
Nasdaq
11,768.84
-55.12(-0.47%)
BTC-USD
27,099.29
-732.40(-2.63%)
CMC Crypto 200
587.32
-20.14(-3.32%)

AZN Jul 2023 80.000 call

OPR - OPR Delayed Price. Currency in USD

Add to watchlist

2.1500

+0.0700

(+3.37%)

As of 11:34AM EDT. Market open.

Zacks
Ionis (IONS) Posts New Upbeat Data From Amyloidosis Drug Study
Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
Business Wire
Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks
WILMINGTON, Del., March 27, 2023--Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen met its co-primary endpoints through 66 weeks. The results were consistent with the positive 35-week findings announced in June 2022.1
Zacks
Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7%
Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.